01—Abstract
Summary
Summary of the 10-K filed February 15, 2024. Cited figures are marked; the original filing is the authoritative source.
IQVIA Holdings Inc. reported 2023 revenues of $14.98 billiona, up $574 million, or 4.0%, from $14.41 billion in 2022, with income from operations of $1.98 billion and net income of $1.36 billion, or $7.29 diluted EPS, compared with $1.09 billion and $5.72 in 2022.
Research & Development Solutions drove growth, with revenues of $8.40 billionb (up 6.0%) and segment profit of $1.92 billion, while Technology & Analytics Solutions revenues rose 2.0% to $5.86 billion and Contract Sales & Medical Solutions declined 2.2% to $727 million. Management highlighted record remaining performance obligations of approximately $31.7 billion and R&D contracted backlog of $29.7 billion, though it noted a more cautious spending environment for Technology & Analytics Solutions clients. The company's effective tax rate fell to 6.9% from 19.1%, largely due to a $125 million benefit from an internal legal entity restructuring, which contributed meaningfully to the earnings increase.
Operating cash flow declined to $2.15 billionc from $2.26 billion. Total debt was $13.75 billion at year-end, and the company ended the year with $1.38 billion in cash, after issuing $1.5 billion of incremental Term B-4 loans and $1.25 billion of 6.250% senior secured notes due 2029 in November 2023, along with $750 million of 5.700% senior secured notes due 2028 and $500 million of 6.500% senior notes due 2030 in May 2023.
IQVIA repurchased $992 milliond of common stock in 2023 and had $2.36 billion remaining under its repurchase authorization. Risk factors highlighted client contract cancellations and delays, data-supplier dependence, data privacy regulation, and the pending Veeva litigation, in which the company is the plaintiff and Veeva has counterclaimed for damages in excess of $200 million.
02—Key points
Key Highlights
- Revenue rose 4.0% to $14.98 billion in 2023; Research & Development Solutions grew 6.0% to $8.40 billion, the largest segment.
- Net income increased to $1.36 billion from $1.09 billion, with diluted EPS of $7.29 versus $5.72 in 2022.
- Effective income tax rate dropped to 6.9% from 19.1%, aided by a $125 million benefit from an internal legal entity restructuring.
- Record remaining performance obligations of approximately $31.7 billion; R&D contracted backlog reached $29.7 billion.
- Total debt of $13.75 billion at year-end; 2023 included $4.0 billion of debt proceeds and new senior secured and senior notes issuances.
- Operating cash flow was $2.15 billion, down from $2.26 billion, while $992 million was spent on share repurchases.
- Contract Sales & Medical Solutions revenue declined 2.2% to $727 million, and Technology & Analytics Solutions growth slowed to 2.0%.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 15, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $14.98B$14.41B | +4.0% |
| SG&A Expenses | $2.05B$2.07B | −0.9% |
| Operating Income | $1.98B$1.80B | +9.9% |
| Interest Expense | $672.00M$416.00M | +61.5% |
| Net Income | $1.36B$1.09B | +24.5% |
| EPS (Basic) | $7.39$5.82 | +27.0% |
| EPS (Diluted) | $7.29$5.72 | +27.4% |
| Shares Outstanding (Basic) | 183.80M187.60M | −2.0% |
| Shares Outstanding (Diluted) | 186.30M190.60M | −2.3% |
05—Questions
Frequently Asked Questions
What drove IQVIA's earnings growth in 2023?
Income from operations rose to $1.98 billion from $1.80 billion, and net income increased to $1.36 billion from $1.09 billion. The filing attributes growth in part to productivity initiatives, and the lower effective tax rate of 6.9%, which reflects a $125 million benefit from an internal legal entity restructuring, also contributed significantly.
How did each business segment perform?
Research & Development Solutions revenue grew 6.0% to $8.40 billion, with segment profit up 13.0% to $1.92 billion. Technology & Analytics Solutions revenue rose 2.0% to $5.86 billion, but segment profit fell 3.9% to $1.49 billion. Contract Sales & Medical Solutions revenue fell 2.2% to $727 million, while segment profit rose to $49 million from $42 million.
What is the company's debt and liquidity position?
Total indebtedness was $13.75 billion as of December 31, 2023, excluding $1.90 billion of available revolving credit capacity. Cash and cash equivalents were $1.38 billion. Management stated it believes available cash, operating cash flows and revolving and receivables facilities will fund operations and debt obligations for at least the next 12 months.
What are the key risks highlighted in the filing?
Key risks include the ability of most R&D Solutions clients to terminate contracts on 30 to 90 days' notice, dependence on third-party data suppliers, cybersecurity threats, and data privacy laws such as HIPAA and GDPR. The filing also flags variable-rate debt exposure, foreign currency fluctuations, and the pending Veeva litigation, in which Veeva has asserted counterclaims for damages in excess of $200 million.
How much capital did IQVIA return to shareholders?
IQVIA repurchased 5.0 million shares for approximately $992 million in 2023 under its repurchase program. The Board increased the total authorization by $2.00 billion on July 31, 2023, bringing it to $11.73 billion, of which $2.36 billion remained available at year-end. The company paid no dividends in 2023 and does not currently intend to pay them.
06—Continue